Novavax, Inc.
NVAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Novavax, Inc. focuses on Biotechnology services and products. Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and. The company carries a $1.80B market cap, placing it firmly in the small-cap category. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Market Cap
$1.80B
Beta
2.37
P/E (TTM)
—
P/E (Fwd)
-20.22
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.54
ROE
—
ROA
2.0%
Cash
$790.3M
Total Debt
$295.1M
Free CF
$58.6M
52W Change
55.2%
Annual Financials
Cash vs Debt
With $790.3M in cash and $295.1M in debt, NVAX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $58.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $1.60B to $1.12B.
With a beta above 1.5, NVAX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NVAX has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing NVAX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.